Generex Biotechnology Corporation (NASDAQ: GNBT), a biopharmaceutical company, has a diversified product portfolio designed to deliver innovative products to treat patients with cancer. DNA/RNA-based Medicines and Small Molecules are the two major programs that anchor the Company’s research platform. Ganite® (gallium nitrate injection) is the company’s leading drug in the Small Molecule program. Ganite is exclusively marketed in the U.S. to treat symptomatic patients with cancer-related hypercalcemia that is resistant to hydration. For further information, visit the Company’s web site at www.genta.com.
- 18 years ago
QualityStocks
Generex Biotechnology Corporation (NASDAQ: GNBT)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – Nightfood Holdings Inc. (OTCQB: NGTF) Launches Strategic Robotics Partnership Initiative With ToDo Robotics
Nightfood Holdings (OTCQB: NGTF), through its TechForce Robotics division, announced a strategic partnership initiative with…
-
QualityStocksNewsBreaks – Planet Ventures Inc. (CSE: PXI) (OTC Pink: PNXPF) (FSE: P6U) Invests in Reusable Satellite Startup Lux Aeterna
This article has been disseminated on behalf of Planet Ventures Inc. and may include paid…
-
QualityStocksNewsBreaks – Frontieras North America Inc. Advancing FASForm(TM) for Domestic, Feedstock-Driven Energy Production
Frontieras is positioned amid increased demand for domesticenergy production. “At the core of its strategy is…